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Short Heading: 
Immediate Sequential Bilateral Cataract Surgery in the UK  
 
 
Summary 
What was known before: 
- NICE concluded that ophthalmologists may consider offering ISBCS to two groups of 
patients with bilateral cataract; high risk general anaesthetic patients and low-risk 
routine patients  
- In some high-income countries, ISBCS has become an established national pathway 
offered to patients 
- Other than historic case series, there have not been any reports of ISBCS being 
performed at scale in the UK 
What this study adds: 
- Less than 0.5% of the cataract operations performed in the UK between 2010 and 
2018 were ISBCS 
- The case mix suggests that the majority of patients are offered ISBCS because they fall 
into the high-risk general anaesthesia category 
- ISBCS patients were younger, had more difficulties with cooperating and lying flat, 
worse pre-operative vision, and higher rates of known PCR risk factors than those on 
the delayed sequential cataract surgical pathway 
- This study provides evidence that no centre contributing to the NOD routinely 
performed ISBCS to treat low risk bilateral cataracts between 2010-2018 
 
  
Abstract (250 words) 
Background 
Cataract extraction is the most frequently performed surgical intervention in the world and 
demand is rising due to an ageing demography. One option to address this challenge is to 
offer selected patients immediate sequential bilateral cataract surgery (ISBCS). This study 
aims to investigate patient and operative characteristics for ISBCS and delayed bilateral 
cataract surgery (DSCS) in the UK. 
Methods 
Data was analysed from the Royal College of Ophthalmologists’ National Ophthalmology 
Database Audit (NOD) of cataract surgery. Eligible patients were those undergoing bilateral 
cataract extraction from centres with a record of at least one ISBCS operation between 
01/04/2010 and 31/08/2018. Variable frequency comparison was undertaken with chi-square 
tests. 
Results 
During the study period, 1,073 patients had ISBCS and 248,341 DSCS from 73 centres. A higher 
proportion of ISBCS patients were unable to lie flat (11.3% vs. 1.8%; p <0.001), unable to 
cooperate (9.7% vs. 2.7%; p <0.001); underwent general anaesthesia (58.7% vs. 6.6% (p < 
0.001)); had brunescent/white/mature cataracts (odds ratio (OR) 5.118); no fundal view / 
vitreous opacities (OR 8.381); had worse pre-operative acuity 0.60 LogMAR ISBCS vs. 0.50 
(first) and 0.40 (second eye) DSCS and were younger (mean ages, 71.5 vs. 75.6 years; p < 
0.001). Posterior capsular rupture (PCR) rates adjusted for case complexity were comparable 
(0.98% ISBCS and 0.78% DSCS). 
Conclusions 
ISBCS was performed on younger patients, with difficulty cooperating and lying flat, worse 
pre-operative vision, higher rates of known PCR risk factors and more frequent use of general 
anaesthesia than DSCS in centres recorded on NOD. 
  
Introduction 
Cataract surgery is the most common surgical intervention in the world, and almost half a 
million cataract operations are now done each year in the UK (≈430,000 NHS cataracts in 
England and Wales 2017/18). Cataract surgery is established as a highly cost-effective 
intervention with substantial quality of life gains on offer for patients, both for first and 
second eye surgeries.[1] It has been suggested that offering patients surgery for both eyes on 
the same day, termed immediate sequential bilateral cataract surgery (ISBCS), could achieve 
full quality of life gains faster, whilst more effectively using the finite financial, environmental 
and human resources available to the UK NHS.  
 
Taking an estimate of £1,000 per completed one-eye cataract pathway, the NHS spend is 
therefore nearing £500 million annually.[2] With an aging population, this cost is set to 
increase by 50% in the next 20 years;[3] however, a 50% increase in either the financial or the 
human resources available to deliver that service is not widely anticipated. Unless there are 
substantial changes to current NHS working practices, rationing of cataract surgery will be 
inevitable, either explicitly by setting treatment thresholds or covertly, by waiting lists. 
 
Rationing of cataract surgery in the UK is already occurring.[4, 5] This is true despite the 2017 
NICE guidance on adult cataract management [NG77] stating that rationing and delay of 
surgery once sight impairment from cataract has been identified is not justifiable on cost or 
clinical grounds.[6] 
 
If we are to mitigate the effects of the demographic time bomb,[7] encouraging providers to 
offer ISBCS potentially offers a more cost-effective and sustainable pathway, with reduced 
outpatient visits, enhanced operating theatre efficiency through shorter surgical turnaround 
times between operations, and reduced carbon footprint.[8] 
 
The NICE Cataract Guidelines [NG77] suggest that clinicians may consider offering ISBCS to 
two groups of patients with bilateral cataract: 
 
1: people who are at low risk of ocular complications during and after surgery. 
2: people who need to have general anaesthesia for cataract surgery but for whom general 
anaesthesia carries an increased risk of complications or distress.[6] 
 
Previous published UK case series exist of patients in the high-risk GA category being offered 
ISBCS,[9]) but there is no published evidence regarding how widespread this practice is 
presently, and whether ISBCS is being offered to patients in the low-risk category – who would 
be expected to form the majority of the half million eyes operated for cataract each year. 
 
This analysis of data submitted to the Royal College of Ophthalmologists’ National 
Ophthalmology Database Audit (RCOphth NOD),[10] aims to describe current practice in 
ISBCS provision in contributing centres as representative of English and Welsh ophthalmic 
departments. Differences between patients with bilateral cataract undergoing ISBCS and 
those undergoing delayed sequential surgery (DSCS) are described, so as to typify current 
ISBCS patients and evaluate how current practice reflects the NICE guidance. 
 
 
Methods 
The RCOphth NOD receives anonymised data from participating NHS Trusts in England, Health 
Boards in Wales and Independent Sector Treatment Centres (ISTC) providing NHS Funded 
cataract surgery in England, Wales and one ISTC in Guernsey. The data is recorded on 
electronic medical record systems (EMR) or in-house databases and extracted in the autumn 
of each year for cataract operations using phacoemulsification to treat patients aged 18 years 
or older, where the primary intention was cataract surgery and not combined ‘cataract + 
other’ surgery, unless the ‘other’ surgery formed part of the cataract operation (e.g. an 
operative manoeuvre to increase the size of the pupil). Further information on an audit 
eligible cataract operation can found on the audit website (www.nodaudit.org.uk).  
 
Centres contributing to the RCOphth NOD may reasonably be taken as a surrogate for practice 
in England and Wales as a whole, with the last data extraction providing ~216,000 operations 
from 101 centres, well over half (~60%) of the traditional NHS providers. 
 The analysis presented in this manuscript concerns cataract operations satisfying all bar the 
centre location eligibility criteria that applies to National Ophthalmology Audit (NOA), from 
any RCOphth NOD contributing centre with at least 50 NOA eligible cataract operations 
performed between 01/04/2010 and 31/08/2018. Only centres with a record of at least one 
ISBCS operation where both eye operations satisfied the NOA eligibility criteria during the 
study period are included. For comparison, DSCS patients are those from these centres who 
had both eyes undergo NOD eligible cataract surgery where the second eye surgery was 
conducted within one year of the first. The data was recorded on either the Medisoft EMR 
system (Medisoft Ophthalmology, Medisoft Limited, Leeds, UK, www.medisoft.co.uk), the 
Open Eyes EMR system (www.openeyes.org.uk), or ‘in-house’ data collection systems 
compliant with the National Cataract Dataset.[11] 
 
Pre-operative visual acuity (VA) was defined as the best recorded distance VA (corrected or 
uncorrected but not pinhole) that is closest to the date of surgery, including the day of surgery 
and within 6 months prior to surgery. For numeric calculations, the extreme low vision 
estimates from the LogMAR chart representing count fingers (CF), hand movements (HM), 
perception of light (PL) and no perception of light (NPL) are replaced with 2.10, 2.40, 2.70 and 
3.00 respectively. 
 
Posterior Capsular Rupture (PCR) was defined as in the NOA and case complexity expected 
and adjusted rates were calculated using the case complexity adjustment from the NOA, 
where full details about the adjustment can be found on the audit website 
(www.nodaudit.org.uk). The variables used for case complexity adjustment are the surgeon 
grade, first/second eye surgery and all variables marked with (#) in tables 1 and 2. For the 
ISBCS patients, both eyes are assumed to be the first treated eye in the case complexity 
adjustment. 
 
Comparisons at the patient level are performed between ISBCS patients and at the first eye 
surgery for DSCS patients using χ2 tests except for the comparison of the patient’s age which 
was performed using the student’s t-test with the Welch adjustment. Comparisons at the eye 
level were performed using univariate logistic regression with cluster adjustment for the 
standard errors where the patients are considered as the clusters. 
 
The lead clinician and Caldicott Guardian (responsible nominee for data protection) at each 
centre provided written approval for anonymised data extraction. Anonymized database 
analyses of this type do not require ethical permission due to being viewed as audit or service 
evaluation (see http://www.hra.nhs.uk/research-community/before-you-
apply/determinewhether-your-study-is-research/). This study was conducted in accordance 
with the declaration of Helsinki, and the UK’s Data Protection Act. 
 
 
Results: 
Patient demographics 
During the study period, 1,073 patients had ISBCS and 248,341 patients DSCS from 73 centres; 
thus from centres doing any ISBCS in the study period, 0.43% were ISBCS. 
The median time between the first eye and second eye surgery for the DSCS patients was 3.4 
months. The second eye surgery was performed within 3 months of the first eye surgery for 
110,337 (44.4%) DSCS patients and within 6 months for 209,839 (84.5%) DSCS patients. 
Of the ISBCS patients, 671 (62.5%) were female vs. 149,076 (60.0%) of DSCS patients (p = 
0.160). Using the first eye surgery of the DSCS patients as the comparator, the ISCBS patients 
tended to be younger than the DSCS patients, mean ages 71.5 years vs. 75.6 years (p < 0.001) 
(Figure 1), and 39.5% of ISBCS patients were aged <70 years old vs. 25.0% of DSCS patients. A 
lower proportion of ISBCS patients had diabetes mellitus than DSCS patients (14.3% vs. 18.1%, 
p < 0.001). More ISBCS patients were unable to lie flat during surgery than DSCS patients 
(11.3% vs. 1.8%, p < 0.001), and more ISBCS patients were unable to cooperate during surgery 
than DSCS patients (9.7% vs. 2.7%, p < 0.001), Table 1. 
 
Operative details 
General anaesthesia was administered to 630 (58.7%) ISBCS patients vs. 16,429 (6.6%) DSCS 
patients (either operation) (p < 0.001). The 2,146 ISBCS operations were performed by 431 
individual surgeons, where consultant surgeons performed 1,815 (84.6%) of the operations 
and trainee surgeons 331 (15.4%) operations and for 997 (92.9%) patients (1,994 operations) 
both ISBCS operations were performed by the same surgeon. 
 
Ocular co-pathology and known PCR risk factors 
At least one ocular co-pathology or known risk factor for PCR was present in 1,012 (47.2%) 
ISBCS eyes and 190,326 (38.3%) DSCS eyes, where the OR for the higher rate in ISBCS eyes 
was 1.436 (95% CI: 1.282 to 1.610; p < 0.001). 
Brunescent / white / mature cataracts were recorded for 14.9% ISBCS eyes vs. 3.3% DSCS 
eyes, OR 5.118 (95% CI: 4.367 to 5.999; p < 0.001). No fundal view / vitreous opacities were 
recorded for 6.6% ISBCS eyes vs. 0.8% DSCS eyes, OR 8.381 (95% CI: 6.647 to 10.568; p < 
0.001). The other ocular co-pathology or known PCR risk factors that were statistically more 
frequently recorded for ISBCS eyes than DSCS eyes were high myopia, optic nerve / CNS 
disease, unspecified ‘other’ and inherited eye diseases which although had a massive OR of 
10.982 is one of the rarest conditions and would include different very rare inherited diseases. 
Age-related macular degeneration was the only ocular co-pathology or known PCR risk factor 
that was more frequently recorded for DSCS eyes than ISBCS eyes, consistent with the 
younger age of the ISBCS patients. 
No individual ocular co-pathology or known PCR risk factor was more frequently recorded for 
the second eye operation than the first eye operation for the DSCS patients. The following 
ocular co-pathologies / risk indicators for PCR were more frequently recorded by >0.5% points 
in DSCS patients first eye operation than their second eye operation; brunescent / white / 
mature cataract, high myopia, no fundal view / vitreous opacities, previous vitrectomy and 
unspecified ‘other’, Table 2. 
 
Operative complications 
An intra-operative complication occurred in 76 (3.5%) ISBCS eyes and 12,792 (2.6%) DSCS 
eyes, with an OR of 1.389 (95% CI: 1.082 to 1.782; p = 0.010) for the higher rate in ISBCS eyes 
than DSCS eyes. For the DSCS patients, an intra-operative complication occurred in 6,230 
(2.5%) first eye operations and 6,562 (2.6%) second eye operations. 
PCR occurred in 41 (1.9%) ISBCS eyes and 5,720 (1.2%) DSCS eyes with an OR of 1.672 (95% 
CI: 1.220 to 2.290; p = 0.001) for the higher rate in ISBCS eyes than DSCS eyes. For the DSCS 
patients, PCR occurred in 2,612 (1.1%) first eye operations and 3,108 (1.3%) second eye 
operations. The expected rate PCR (adjusted according to the frequency of known risk factors 
in those patients) was 2.15% (95% CI: 1.61% to 2.85%) for ISBCS eyes and 1.63% (95% CI: 
1.60% to 1.67%) for DSCS eyes, and the case complexity adjusted rate of PCR was 0.98% (95% 
CI: 0.64% to 1.49%) for ISBCS eyes and 0.78% (95% CI: 0.75% to 0.80%) for DSCS eyes, both 
lower than the overall consultant rate of 1.1% used in The National Cataract Audit. 
 
Pre-operative visual acuity 
A pre-operative visual acuity (VA) measurement was recorded for 1,790 (83.4%) ISBCS eyes, 
where the median pre-operative VA was 0.60 LogMAR (6/24 Snellen equivalent). For 418 
(23.4%) ISBCS eyes the pre-operative VA was CF or worse and the pre-operative VA 
distribution was very similar for ISBCS patients left and right eyes. 
For the DSCS patients first eye operation, a pre-operative VA was recorded for 236,304 
(95.2%) eyes, where the median pre-operative VA was 0.50 LogMAR (6/19 Snellen equivalent) 
and for 11,893 (5.0%) eyes the pre-operative VA was CF or worse. 
For the DSCS patients second eye operation, a pre-operative VA was recorded for 229,564 
(92.4%) eyes, and in contrast to the first eye operation the pre-operative VA profile was 
generally better for the second eye operation, where the median pre-operative VA was 0.40 
LogMAR (6/15 Snellen equivalent) and for 7,025 (3.1%) eyes the pre-operative VA was CF or 
worse, Figure 2 and Table 3. 
 
Discussion 
For over three decades, articles in peer reviewed journals have asked if ISBCS is a practice the 
NHS should be adopting as routine.[12-14] Despite this interest, our study demonstrates that 
ISBCS is being performed for a small number of higher complexity patients, evidenced by their 
issues with cooperating, lying flat, higher rates of brunescent / white / mature cataracts and 
no fundal view / vitreous opacities. 
 
Relating to current NICE guidance, the preponderance of these factors in the ISBCS groups 
and the finding that nearly 60% of ISBCS operations were carried out under GA suggests that 
ISBCS is being offered to “people who need to have general anaesthesia for cataract surgery 
but for whom general anaesthesia carries an increased risk of complications or distress.” The 
other category for whom NICE suggest consideration of ISBCS be given, “people who are at 
low risk of ocular complications during and after surgery”, who would be expected to 
constitute the majority of those undergoing surgery for bilateral lens opacity, are therefore 
shown to be either not offered this surgical option, or to be universally declining it. 
 
It is possible that ISBCS is being offered to low-risk patients by surgeons who are not yet 
contributing their data to the RCOphth NOD. However, based on two recent surveys 
undertaken to identify uptake of ISBCS as a surgical option in UK ophthalmology departments 
this seems unlikely. In 2016, UK lead clinicians were surveyed by email using the RCOphth 
database; no department reported offering ISBCS to routine patients from 42 responses, and 
only 14% (6/42) reported that they would offer ISBCS to individual patients according to 
specific need (unpublished data – personal communication (A. Azuara-Blanco). The same 
finding was reported from the RCOphth Way Forward project which requested phone 
interviews with consultants nominated as leading cataract services in their units; 50 
consultants from across the UK were interviewed (representing 50/142 UK NHS eye 
departments) and none were found to be offering ISBCS routinely.[7] 
 
Unless both of these surveys and NOD data recruitment suffer from the same systematic 
biases, the assertion that the RCOphth NOD data reflects the UK national practice of ISBCS 
seems reasonable. Internationally, there has been adoption of ISBCS in a small number of 
countries as a mainstream option for patients with bilateral cataract, particularly in areas of 
lower population density where travel times are substantial (parts of Scandinavia, Spain and 
Canada).[15] Experience from those settings has been encouraging but the evidence base has 
not proved sufficiently strong to convince either NICE or UK ophthalmologists to feel 
confident to make ISBCS widely available to patients.  
 
The decision to offer or not offer ISBCS is made by individual ophthalmologists. Other than 
reducing theatre turnaround time, there is no incentive for the surgeon to make ISBCS 
available as it creates an administrative burden to organise separate batch numbers for all 
consumables used intra-operatively. The lack of incentive is compounded by the perception 
of increased risk to the patient due to reports of clustering of endophthalmitis cases,[16] 
which may not be entirely mitigated by separation of consumable batch numbers and 
instrument sterilisation timings. There is a further resource burden when general anaesthesia 
is used for surgery. 
 
From the patients’ perspective, there is some evidence that a prolonged gap between first 
and second eye surgery, in our series a median of 3.4 months, can increase the risk of falls,[17] 
and diminish the quality of some patients’ final visual function with poorer stereopsis, greater 
exophoria and reduced near point convergence.[18] On the other hand, it has been shown 
theoretically that delaying second eye surgery until the refractive outcome from the first eye 
is known may improve overall refractive outcome,[19] but superiority of refractive outcomes 
of DSBCS over ISBCS in large case series has not been demonstrated.[20] Despite arguments 
either way, the general assumption amongst the ophthalmic community is that the final 
outcome of bilateral cataract surgery will be the same whether the two operations are 
performed on the same day, or some weeks apart.  
 
It may be that the unsubstantiated perception of the absence of benefit to patients, along 
with the perception of increased risk of bilateral complications are insurmountable barriers 
unless better evidence is generated to inform the debate. Given the rarity of the most serious 
post-operative complications of cataract surgery (including non-ocular complications such as 
falls and road traffic accidents), it would not be possible to produce high-level evidence of the 
relative risks of different pathways. The question of patient benefit centres around the more 
rapid achievement of quality of life gains and avoidance of inter-operative imbalance, could 
however be informed by a randomised controlled trial, powered to cost-effectiveness, where 
effectiveness is defined in terms of patient centred outcomes and the area under curve of the 
improvement of quality of life generated by the surgical pathway. Further studies should 
include qualitative investigation of the perceptions of risk and how these are understood by 
patients and clinicians, along with exploration of the ethical issues of allowing patients to 
choose pathways with which some clinicians feel uncomfortable.  
 
Unless there is a very large and currently unanticipated change in the global demographic, 
the treatment options for cataract, or the resources available to deliver health services, it is 
unavoidable that current cataract services will have to evolve. Sustainability is an increasingly 
important agenda for healthcare as a whole, and the environmental necessity to reduce our 
collective carbon footprint is pressing. ISBCS is an option that potentially offers benefits to 
patients, whilst meeting these challenges, but this study demonstrates that it is an option that 
has been largely ignored in the UK thus far.  
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Table 1: Demographics for the ISBCS and DSCS patients 
N (Column %) ISBCS DSCS Overall p-value 
Number of patients 1,073 248,341 249,414 - 
Patients gender (#)     
Male 402 (37.5) 99,037 (39.9) 99,439 (39.9) 
0.160 Female 671 (62.5) 149,076 (60.0) 149,747 (60.0) 
Not recorded 0 (0.0) 228 (<0.1) 228 (<0.1) 
Patients age (years)* (#)     
Median 74.6 76.9 76.9 
- Inter-Quartile range 62.7 – 82.2 70.0 – 82.4 70.0 – 82.4 
Range 21.4 – 100.6 18.0 – 112.5 18.0 – 112.5 
Mean 71.5 75.6 75.5 <0.001 
<70 424 (39.5) 62,009 (25.0) 62,433 (25.0) 
<0.001 
70 – 74 127 (11.8) 42,508 (17.1) 42,635 (17.1) 
75 – 79 181 (16.9) 54,901 (22.1) 55,082 (22.1) 
80 – 84 166 (15.5) 51,186 (20.6) 51,352 (20.6) 
85 – 89 114 (10.6) 28,959 (11.7) 29,073 (11.7) 
≥90 61 (5.7) 8,778 (3.5) 8,839 (3.5) 
Patient with the following*     
Diabetes Mellitus 153 (14.3) 45,070 (18.1) 45,223 (18.1) <0.001 
Could not lie flat during surgery (#) 121 (11.3) 4,496 (1.8) 4,617 (1.9) <0.001 
Could not cooperate with the 
surgery 
104 (9.7) 6,674 (2.7) 6,778 (2.7) <0.001 
 
*These estimates for the DSCS patients are at the time of their first eye cataract surgery, and 
some of these could be different at the time of their second eye cataract surgery. 
Statistical comparisons performed using χ2 tests except for the comparison of the patient’s 
age which was performed using the student’s t-test with the Welch adjustment. 
(#)These conditions are included in the case complexity adjustment for PCR. 
  
Table 2: Ocular co-pathology and known risk factors for the ISBCS and DSCS operations 
N (Column %) 
ISBCS eyes 
(N = 2,146) 
DSCS eyes 
(N = 496,682) 
OR 95% CI for OR p - value 
% of DSCS eyes at 
their: 
First 
eye 
surgery 
Second 
eye 
surgery 
No ocular co-pathology or 
know risk factors 
1,134 (52.8) 
306,356 
(61.7) 
1.436 1.282 to 1.610 <0.001 
59.4 64.0 
At least one ocular co-
pathology or known risk 
factor 
1,012 (47.2) 
190,326 
(38.3) 
40.6 36.0 
The presence of        
Age-related macular 
degeneration 
147 (6.9) 47,123 (9.5) 0.702 0.558 to 0.882 0.002 9.6 9.3 
Amblyopia (#) 34 (1.6) 7,835 (1.6) 1.004 0.690 to 1.462 0.982 1.7 1.4 
Brunescent / white / mature 
cataract (#) 
319 (14.9) 16,385 (3.3) 5.118 4.367 to 5.999 <0.001 4.2 2.4 
Corneal pathology 62 (2.9) 14,142 (2.8) 1.015 0.725 to 1.421 0.930 3.0 2.7 
Diabetic retinopathy (#) 113 (5.3) 25,299 (5.1) 1.036 0.799 to 1.342 0.791 5.1 5.1 
Glaucoma 152 (7.1) 39,346 (7.9) 0.886 0.706 to 1.113 0.298 8.1 7.7 
High myopia (#) 139 (6.5) 24,034 (4.8) 1.362 1.074 to 1.727 0.011 5.3 4.4 
Inherited eye diseases 31 (1.4) 662 (0.1) 10.982 6.616 to 18.229 <0.001 0.1 0.1 
No fundal view / vitreous 
opacities (#) 
142 (6.6) 4,164 (0.8) 8.381 6.647 to 10.568 <0.001 1.3 0.4 
Other macular pathology 25 (1.2) 8,522 (1.7) 0.675 0.424 to 1.076 0.099 1.8 1.7 
Other retinal vascular 
pathology 
13 (0.6) 3,416 (0.7) 0.880 0.440 to 1.761 0.718 0.7 0.7 
Optic nerve / CNS disease 24 (1.1) 1,705 (0.3) 3.283 1.900 to 5.675 <0.001 0.4 0.3 
Pseudoexfoliation / 
Phacodenesis (#) 
21 (1.0)) 4,100 (0.8) 1.187 0.671 to 2.102 0.556 0.9 0.8 
Previous retinal detachment 9 (0.4) 2,079 (0.4) 1.002 0.486 to 2.067 0.996 0.6 0.2 
Previous vitrectomy 20 (0.9) 3,538 (0.7) 1.311 0.764 to 2.249 0.325 1.0 0.4 
Previous trabeculectomy (#) 3 (0.1) 1,439 (0.3) 0.482 0.155 to 1.497 0.207 0.3 0.3 
Uveitis / Synaechiae 13 (0.6) 2,923 (0.6) 1.029 0.483 to 2.196 0.940 0.7 0.5 
Unspecified ‘other’ ocular 
co-pathology (#) 
148 (6.9) 26,896 (5.4) 1.294 1.034 to 1.619 0.024 6.0 4.9 
(#)These conditions are included in the case complexity adjustment for PCR.  
CI = confidence interval 
Table 3: Pre-operative LogMAR visual acuity 
 ISBCS patients DSCS patients Overall 
N (%) Left eyes Right eyes 
First eye 
surgery 
Second eye 
surgery 
 
Number of eyes 1,073 1,073 248,341 248,341 498,828 
Number without VA data 177 (16.5) 179 (16.7) 12,037 (4.8) 18,777 (7.6) 31,170 (6.2) 
Number with VA data 896 (83.5) 894 (83.3) 236,304 (95.2) 229,564 (92.4) 467,658 (93.8) 
Median 0.60 0.60 0.50 0.40 0.50 
Inter quartile range 0.30 - 1.50 0.40 - 1.50 0.30 – 0.70 0.20 – 0.60 0.30 – 0.64 
Range -0.20 - NPL -0.30 - NPL -0.30 - NPL -0.30 - NPL -0.30 - NPL 
Number with      
CF 87 (9.7) 80 (8.9) 7,420 (3.1) 5,114 (2.2) 12,701 (2.7) 
HM 70 (7.8) 79 (8.8) 3,544 (1.5) 1,626 (0.7) 5,319 (1.1) 
PL 49 (5.5) 44 (4.9) 871 (0.4) 267 (0.1) 1,231 (0.3) 
NPL 4 (0.4) 5 (0.6) 58 (<0.1) 18 (<0.1) 85 (<0.1) 
 
  
Figure legends: 
 
Figure 1: 
Cumulative frequency of the patient’s age in years: N = 1,073 patients treated with ISBCS and 
248,341 patients treated with DSCS at the time of their first cataract surgery. 
 
Figure 2: 
Cumulative frequency of LogMAR pre-operative visual acuity for ISBCS patients left and right 
eyes and DSCS patients first and second treated eyes: N = 896 ISBCS patients left eyes, 894 
ISBCS patients right eyes, 236,304 DSCS patients first eye surgery and 229,564 DSCS patients 
second eye surgery. 
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